Bayer’s asundexian fails key atrial fibrillation study

20 Nov 2023

Phase 3

Bayer suffered a setback in its efforts to develop asundexian after the oral FXIa inhibitor failed to work as well as Pfizer and Bristol Myers Squibb’s direct oral anticoagulant Eliquis (apixaban) in patients with atrial fibrillation. The company’s shares plunged nearly as much as 18% on Monday.

The Phase III OCEANIC-AF study compared once-daily asundexian to Eliquis in patients with atrial fibrillation at risk for stroke with the trial designed to assess prevention of stroke and systemic embolism. Bayer said that an independent data monitoring committee recommended stopping the study early due to the “inferior efficacy” of asundexian.

More to come.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Bayer AG

Pfizer Inc.

Bristol Myers Squibb Co.

Indications

Atrial FibrillationStrokeSystemic embolism

Targets

Drugs

BMS-962212ApixabanAsundexian

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.